Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Mosonmagyaróvár

479 clinical trials in Mosonmagyaróvár, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mosonmagyaróvár at a glance
479
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

479 trials in Mosonmagyaróvár

Open in trial search

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen - Cilag International

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:Astrazeneca AB

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid
  • Sponsor:Eli Lilly & Co.

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:PF-07275315
  • Sponsor:Pfizer Inc.

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Mosonmagyaróvár

What the registry says about research in the country

01 Respiratory Medicine

Multiple innovative trials focusing on moderate to severe asthma management, testing new therapeutic approaches including lunsekimig, dupilumab, and amlitelimab. Research aims to prevent lung function decline and reduce exacerbations.

  • Asthma Exacerbation Prevention
  • Lung Function Preservation
  • Novel Treatment Evaluation

Studies particularly emphasize long-term safety and efficacy in patients with eosinophilic phenotype.

02 Pulmonary Disease Management

Clinical research focusing on Chronic Obstructive Pulmonary Disease (COPD), evaluating new treatments like itepekimab and investigating improved delivery systems for existing medications.

  • COPD Exacerbation Reduction
  • Long-term Treatment Safety
  • Inhaler Technology Innovation

Emphasis on moderate to severe COPD patients and former smokers.

03 Cardiovascular Research

Comprehensive studies in heart failure and atrial fibrillation, testing breakthrough treatments including ponsegromab, milvexian, and vericiguat for improved patient outcomes.

  • Stroke Prevention
  • Heart Failure Management
  • Cardiovascular Event Prevention

Focus on reducing major adverse cardiovascular events and improving quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.